Lab Information
Waqqas Afif (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoringResearch Interests
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.Team Members
| Name | Position |
|---|
Latest Publications
- Afif, W., Arasaradnam, R. P., Abreu, M. T., Danese, S., Sandborn, W. J., Miao, Y., Zhang, H., Panaccione, R., Hisamatsu, T., Scherl, E. J., Leong, R. W., Rowbotham, D. S., Peyrin-Biroulet, L., Sands, B. E. & Marano, C. (2024). Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study. The American journal of gastroenterology.
- Wetwittayakhlang, P., Karkout, K., Wongcha-Um, A., Tselekouni, P., Al-Jabri, R., Afif, W., Wild, G., Bitton, A., Bessissow, T. & Lakatos, P. L. (2024). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 56, p. 35-42.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B. & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. The Journal of rheumatology.
- Al-Jabri, R. & Afif, W. (2023). In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Annals of internal medicine, vol. 176, p. JC82.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B. & Vinet, É. (2024). Serious Infections in Offspring Exposed in Utero to Vedolizumab. Inflammatory bowel diseases, vol. 30, p. 496-498.
- Wetwittayakhlang, P., Verdon, C., Starr, M., Hahn, G. D., Golovics, P. A., Bessissow, T., Afif, W., Wild, G., Bitton, A. & Lakatos, P. L. (2023). Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol. 34, p. 603-610.
- Kablawi, D., Aljohani, F., Palumbo, C. S., Restellini, S., Bitton, A., Wild, G., Afif, W., Lakatos, P. L., Bessissow, T. & Sebastiani, G. (2023). Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases. Crohn's & colitis 360, vol. 5, p. otad004.
- Wetwittayakhlang, P., Golovics, P. A., Khoury, A. A., Ganni, E., Hahn, G. D., Cohen, A., Wyse, J., Bradette, M., Bessissow, T., Afif, W., Wild, G., Bitton, A. & Lakatos, P. L. (2022). Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. Journal of gastrointestinal and liver diseases : JGLD, vol. 31, p. 403-410.
- Heron, V., Li Fraine, S., Panaccione, N., Restellini, S., Germain, P., Candido, K., Bernstein, C. N., Bessissow, T., Bitton, A., Chauhan, U. K., Lakatos, P. L., Marshall, J. K., Michetti, P., Seow, C. H., Rosenfeld, G., Panaccione, R. & Afif, W. (2022). Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology, vol. 5, p. 208-213.
- Hahn, G. D., LeBlanc, J.-F., Golovics, P. A., Wetwittayakhlang, P., Qatomah, A., Wang, A., Boodaghians, L., Liu Chen Kiow, J., Al Ali, M., Wild, G., Afif, W., Bitton, A., Lakatos, P. L. & Bessissow, T. (2022). Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. World journal of gastroenterology, vol. 28, p. 4823-4833.
See also
